CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
This study is for patients with stage III colon cancer that has not spread to another part of the body (lymph nodes that were removed with surgery may contain some cancer).
One of the purposes of this study is to determine if giving patients celecoxib and the standard chemotherapy (FOLFOX) decreases the risk of colon cancer recurrence.
This study is also looking at whether receiving FOLFOX (5-fluorouracil/5-FU, leucovorin, oxaliplatin) chemotherapy for 3 months is as good as 6 months of treatment in preventing colon cancer recurrence.
Celecoxib is a non-steroidal anti-inflammatory drug used to treat patients with arthritis and other painful conditions. Studies have shown that celecoxib may reduce the chance of getting polyps (abnormal growths in the colon that may turn to cancer).
Patients will be seen every 6 months for up to 6 years. During the actual treatment period, patients will be followed more frequently based on the protocol requirements.